The research incentive scheme for companies (RISC) grant is intended to encourage the development of strategic technologies and capabilities in Singapore. CombinatoRx Singapore plans to use this grant to discover and potentially develop novel product candidates to treat infectious diseases.
The Singapore economic development board (EDB) plans and executes strategies to develop Singapore as a compelling global hub for business and investment.
“We are very pleased to be selected for this grant,” commented Alexis Borisy, president and CEO of CombinatoRx. “Singapore’s EDB Biomedical Sciences Group has gone to great lengths to support scientific innovation. This grant will help accelerate the development of novel therapeutics using our combination high throughput screening discovery technology for infectious diseases.”